Page contents Back to list Full notification Final report General information GMO characterization European Commission administrative Information Return to search
Full notification Final report - General information Notification Number B/DE/22/PEI4815 Member State to which the notification was sent Germany Date of acknowledgement from the Member State Competent Authority 17/02/2022 Title of the Project A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma  Proposed period of release: 01/07/2022 to 30/08/2024 Name of the Institute(s) or Company(ies) Kite Pharma, Inc., 2400 Broadway Santa Mónica, CA 90404, U.S.A.
Is the same GMO been notified elsewhere by the same notifier? Yes:
Netherlands;
Has the same GMO been notified elsewhere by the same notifier? No GMO characterization GMO is a: Other Identity of the GMO: Human T cells transduced with a bicistronic, replication-deficient lentiviral delivery system (293T-K363 Vector) to express chimeric antigen receptors (CARs) specific for CD19 and CD20 antigens.  Information relating to the recipient or parental organisms from which the GMO is derived Common Name: Human Genus: Homo Species: Homo Sapiens Subspecies: Strain: Pathovar: European Commission administrative Information Consent given by the Member State Competent Authority: Not known
Close
Select your language
English